Information on the target
The target of this acquisition is the microbiology business of Thermo Fisher Scientific Inc., a prominent player in the life sciences and clinical research sectors. Headquartered in Waltham, Massachusetts, this division specializes in providing diagnostic consumables and equipment essential for microbiological testing across various applications, including clinical diagnostics, food safety, and pharmaceutical development. With a robust operational framework, the microbiology business serves a diverse clientele of over 15,000 customers in more than 100 countries.
This business unit employs approximately 2,400 individuals and operates across 13 manufacturing and research & development sites globally. Under the new ownership of Astorg, the microbiology business will transition into an independent entity, with plans to unveil a new corporate brand in 2026, led by CEO Dirk Bontridder.
Industry overview in the target’s specific country
The Medical Diagnostic & Testing Equipment industry in the United States is characterized by rapid innovation and significant investment in research and development. The sector has seen a surge in demand for advanced diagnostic tools, driven by the increasing prevalence of chronic diseases and the growing emphasis on preventive healthcare. As healthcare providers seek to enhance patient outcomes, the need for reliable and efficient diagnostic solutions has become paramount.
In recent years, the U.S. market has experienced a notable shift towards automation and digitalization in diagnostic processes. This trend is fueled by advancements in technology, such as artificial intelligence and machine learning, which are being integrated into diagnostic equipment to improve accuracy and speed. Furthermore, the COVID-19 pandemic has accelerated the adoption of diagnostic testing, highlighting the critical role of medical diagnostic equipment in public health responses.
The regulatory landscape in the U.S. also plays a crucial role in shaping the Medical Diagnostic & Testing Equipment industry. The Food and Drug Administration (FDA) oversees the approval and monitoring of diagnostic devices, ensuring that they meet stringent safety and efficacy standards. This regulatory framework, while rigorous, also fosters innovation by providing a clear pathway for new technologies to enter the market.
Overall, the U.S. Medical Diagnostic & Testing Equipment industry is poised for continued growth, driven by technological advancements, an aging population, and an increasing focus on personali…